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Cholesterol is an essential component of animal cell membranes, and its concentration 
is tightly controlled by a feedback system that operates at transcriptional and posttran-
scriptional levels. Here, we discuss recent advances that explain how cells employ an 
ensemble of membrane-embedded proteins to monitor sterol concentrations and adjust 
sterol synthesis and uptake.Introduction
Among the known feedback control systems in animal cells, 
the cholesterol system is unique in that the regulated end-
product—cholesterol—is sequestered entirely within cell 
membranes. To monitor levels of membrane sterols, cells 
employ two membrane-embedded proteins of the endo-
plasmic reticulum (ER)—Scap and 3-hydroxy-3-methylglu-
taryl coenzyme A reductase (HMG CoA reductase). These 
proteins share a polytopic intramembrane sequence called 
the sterol-sensing domain. Through this domain, sterols 
cause Scap and HMG CoA reductase to bind to Insigs, 
newly characterized membrane proteins of the ER. Upon 
binding Scap and reductase, Insigs exert actions that limit 
cholesterol synthesis. By controlling Scap and reductase, 
Insigs stand at the crossroads between the transcriptional 
and posttranscriptional regulatory mechanisms that assure 
cholesterol homeostasis.
Figure 1 illustrates the domains of the membrane pro-
teins discussed in this review. One of these proteins, Scap, 
is an escort protein for sterol regulatory element binding 
proteins (SREBPs), membrane bound transcription fac-
tors that activate all of the genes required to produce cho-
lesterol (Brown and Goldstein, 1997; Horton et al., 2002). 
Scap binds to SREBPs and escorts them from the ER to 
the Golgi apparatus where the SREBPs are proteolytically 
processed to yield active fragments that enter the nucleus 
(Brown and Goldstein, 1999). This processing is mediated 
by the action of two Golgi-associated membrane bound 
proteases: Site-1 protease, a serine protease of the subtili-
sin family (Espenshade et al., 1999) and Site-2 protease, a 
Zn2+ metalloprotease (Zelenski et al., 1999). When choles-
terol builds up in ER membranes, the Scap/SREBP com-
plex fails to exit the ER, proteolytic processing of SREBPs 
is abolished, and transcription of target genes declines 
(Goldstein et al., 2002).
HMG CoA reductase, the rate-controlling enzyme in 
cholesterol biosynthesis, is also embedded in ER mem-
branes (Figure 1). When certain sterols accumulate, the 
enzyme is rapidly degraded, thereby helping to terminate 
sterol synthesis (Gil et al., 1985; Skalnik et al., 1988). The 
effects of sterols on Scap and HMG CoA reductase are 
mediated through their respective sterol-sensing domains (denoted by SSD in Figure 1; Hua et al., 1996a; Yang et al., 
2000; Sever et al., 2003b). In both cases, sterols cause 
these domains to bind to Insigs (Yang et al., 2002; Sever et 
al., 2003b). Insig binding has dramatically different conse-
quences for Scap and HMG CoA reductase. Upon binding 
Insig, Scap is retained in the ER, whereas the reductase is 
ubiquitinated and degraded.
Role of Insig in Regulating Scap Transport
The manner in which Insigs regulate Scap transport is illus-
trated in Figure 2. Mammalian cells produce three closely 
related isoforms of SREBP, called SREBP-1a, SREBP-1c, 
Figure 1. Domain Structures of Membrane Proteins that 
Regulate Cholesterol
Amino acid numbers refer to human proteins. Vertical bars denote trans-
membrane domains identified by hydropathy plots and verified by topol-
ogy mapping (see text for references). SSD denotes sterol-sensing do-
main. Pro in Site-1 protease denotes propeptide sequence. The catalytic 
triad in Site-1 protease is the hallmark of a serine protease. The HExxH 
motif in Site-2 protease is the hallmark of a Zn2+ metalloprotease.Cell 124, January 13, 2006 ©2006 Elsevier Inc. 35
and SREBP-2 (Brown and Goldstein, 1997). SREBP-1a 
and -1c are produced from the same gene through the 
use of different promoters and alternative splicing. All three 
SREBPs are oriented in ER membranes in a hairpin fashion 
with both the NH2-terminal transcription factor domains and 
the COOH-terminal regulatory domain facing the cytosol. 
These domains are separated by two membrane-span-
ning helices that flank a short loop that projects into the ER 
lumen (Figures 1 and 2). Immediately after their synthesis 
on ER membranes, the SREBPs bind to Scap through an 
interaction between the COOH-terminal regulatory domain 
of the SREBP and the cytosolically-oriented COOH-termi-
nal WD-repeat domain of Scap (Sakai et al., 1997).
Scap is embedded in ER membranes through its 
NH2-terminal domain, which is composed of eight trans-
membrane (TM) helices separated by hydrophilic loops 
(Nohturfft et al., 1998b; Figure 1). TM helices 2–6 comprise 
the sterol-sensing domain (Hua et al., 1996a; Nohturfft et 
al., 1998a). In sterol-depleted cells, the Scap/SREBP com-
plex exits the ER in COPII-coated vesicles that bud from 
ER membranes (Nohturfft et al., 2000; Espenshade et al., 
2002; Sun et al., 2005). Scap mediates this exit by bind-
ing to COPII coat proteins through the general mechanism 
defined for yeast and mammalian membrane proteins that 
move from ER to Golgi (Antonny and Schekman, 2001; 
Aridor et al., 1998; Barlowe, 2002). COPII binding is trig-
gered by Sar1, a small GTP binding protein that attaches 
Figure 2. Insig-Mediated Regulation of Scap/SREBP 
 Transport
(Top panel) When animal cells are deprived of sterols, Scap escorts 
SREBPs from the ER to Golgi by binding to Sec24, a component of the 
Sar1/Sec23/Sec24 complex of the COPII protein coat. Once in the Golgi, 
the SREBPs are proteolytically processed to generate their nuclear forms 
that activate genes for cholesterol synthesis and uptake.
(Bottom panel) Cholesterol negatively regulates ER-to-Golgi transport by 
binding to Scap, thereby changing its conformation and triggering the 
binding of Scap to Insig, an ER anchor protein. Insig prevents the bind-
ing of Scap to COPII proteins, thereby halting transport of SREBPs to 
the Golgi.36 Cell 124, January 13, 2006 ©2006 Elsevier Inc.to ER membranes upon exchanging GTP for GDP (Figure 
2). Membrane bound Sar1 then attracts Sec23/24, a cyto-
solic heterodimer. Upon binding to membranes, the Sec24 
component binds to cargo proteins (such as Scap), and 
the Sec23 component attracts other proteins to form the 
coat of the budding vesicle. In the case of Scap, Sec24 
binds to a hexapeptide sequence, MELADL, located in the 
cytoplasmic loop between TM helices 6 and 7 of Scap. 
Mutations within this sequence abolish Sec23/24 binding 
to Scap and prevent the Scap/SREBP complex from exit-
ing the ER (Sun et al., 2005).
When cholesterol builds up in ER membranes, the sterol 
binds to Scap, and this triggers a conformational change 
that causes Scap to bind to Insig. When Scap binds to 
Insig, the Sar1/Sec23/24 complex can no longer bind to 
Scap, and therefore Scap remains in the ER along with its 
attached SREBP (Sun et al., 2005). Saturable and specific 
binding of cholesterol to Scap has been studied in vitro 
using the purified recombinant membrane domain of Scap 
(TM helices 1–8) and [3H]cholesterol, both of which are 
added to the assay tube in detergent micelles (Radhakrish-
nan et al., 2004). In these assays, Scap behaves like a stan-
dard receptor for cholesterol, although the kinetics of the 
binding reaction are unusual in that both the ligand and the 
receptor must be added in separate detergent micelles. In 
this in vitro reaction, the rate-limiting step is the transfer of 
the [3H]cholesterol from the donor micelles to the acceptor 
micelles that contain Scap.
The cholesterol-triggered conformational change in Scap 
has been monitored in membranes isolated from choles-
terol-treated cells and in membranes from sterol-depleted 
cells that were incubated with cholesterol in vitro (Brown et 
al., 2002; Adams et al., 2003, 2004). In these experiments, 
the conformation of Scap is measured by exposing sealed 
membrane vesicles to an impermeant protease such as 
trypsin. When cholesterol has been added to Scap-con-
taining membranes, the tryptic digestion pattern of Scap 
is altered. A new protease fragment is generated through 
cleavage at arginine-505, which is in the cytosolic loop 
between TM helices 6 and 7 (Brown et al., 2002). In mem-
branes from sterol-depleted cells, this arginine is protected 
from tryptic cleavage, perhaps because it is close to the 
membrane surface. When cholesterol is added to intact 
cells or to sterol-depleted membranes in vitro, arginine-505 
becomes exposed, possibly because it is pushed away 
from the membrane. Interestingly, arginine-505 is located 
in the same cytoplasmic loop as the MELADL sequence 
that binds to COPII proteins. Arginine-505 is at the COOH-
terminal end and MELADL is at the NH2-terminal end of 
this 77 amino acid loop (Sun et al., 2005). Conformational 
changes within this loop may be crucial in the regulation of 
Scap transport.
In its cholesterol bound conformation, Scap binds to 
Insig proteins (Adams et al., 2003; Adams et al., 2004). The 
role of Insigs in Scap transport was first disclosed through 
biochemical studies in cultured cells. In early experiments, 
we noted that overexpression of Scap by transfection led 
to constitutive ER-to-Golgi transport that could no longer 
be prevented by sterols (Hua et al., 1996b). We reasoned 
that the overexpressed Scap had saturated an ER protein 
that was responsible for holding Scap back in the ER and 
that the excess Scap was no longer hindered in moving 
to the Golgi. The same effect could be obtained by simply 
expressing part of the membrane domain of Scap (TM heli-
ces 1–6), which contains the sterol-sensing domain (Yang 
et al., 2000). To isolate the putative ER retention protein, 
we created permanent lines of human kidney 293 cells that 
overexpressed either the TM1–6 fragment of Scap or, as a 
control, the TM1–5 fragment, which did not liberate Scap 
from the ER in the presence of sterols (Yang et al., 2000). 
The cells were incubated with sterols, membranes were 
isolated, and affinity chromatography techniques were 
used to purify the Scap TM fragments and any associated 
proteins. The latter were identified by high-sensitivity mass 
spectroscopy. A protein that copurified with Scap(TM1–6), 
but not with Scap(TM1–5), was identified as one of two 
isoforms of Insig, which we designated Insig-1 (Yang et al., 
2002). When we subsequently found in transfection experi-
ments that Insig-1 coprecipitated with Scap(TM1–6), but 
not Scap(TM 1–5), and observed that coprecipitation of full 
length Scap and Insig-1 occurred only in sterol-enriched 
membranes, we were encouraged to believe that Insig-1 
binding was a physiologically relevant event. This conclu-
sion was confirmed through studies of Scaps with point 
mutations in the sterol-sensing domain that abolish regula-
tion by sterols.
Our laboratory identified three sterol-resistant Scaps 
(D443N, Y298C, and L315F) in unbiased screens designed 
to isolate mutant cells that fail to turn off SREBP process-
ing in the presence of cholesterol or other sterols (Hua et 
al., 1996a; Nohturfft et al., 1998a; Yabe et al., 2002b). After 
the discovery that Insig-1 bound Scap, we showed that 
each of these mutant Scaps had lost the ability to bind to 
Insigs and that this binding defect rendered the cells resis-
tant to the effect of cholesterol in blocking SREBP pro-
cessing (Yang et al., 2002; Yabe et al., 2002b; Adams et al., 
2003). The requirement for the Scap/Insig interaction was 
confirmed in a stringent fashion through studies of SRD-15 
cells, a line of mutant Chinese hamster ovary (CHO) cells 
that lacks all Insig proteins (Lee et al., 2005). In these cells, 
cholesterol cannot block Scap exit from the ER. Regula-
tion is restored by transfecting cells with cDNAs encoding 
either of the two Insig isoforms, Insig-1 or Insig-2.
Insig-1 and Insig-2: Similarities and Differences
The Insig-1 mRNA was originally identified in 1991 as a 
transcript (designated CL-6) that increased in regenerat-
ing rat liver and in cultured rat H35 hepatoma cells after 
treatment with insulin (Mohn et al., 1991). Later, CL-6 was 
renamed Insig1 to denote “insulin-induced gene” (Peng et 
al., 1997). Our laboratory rediscovered the Insig-1 mRNA 
as a target of SREBP action in a differential expression 
screen of cultured cells (Luong, 2000). In reinvestigating 
the insulin induction of Insig-1 mRNA, we found that the 
insulin effect was indirect, resulting from insulin’s potent 
stimulation of SREBP-1c gene transcription, which in turn led to a secondary activation of Insig-1 transcription (dis-
cussed below). Insig-2 was discovered in 2002 through 
bioinformatics as a closely related isoform that resembled 
Insig-1 in its Scap binding function but differed in its pat-
tern of regulation (Yabe et al., 2002a).
Human Insig-1 and Insig-2 contain 277 and 225 amino 
acids, respectively (Figure 1). Both Insigs are extremely 
hydrophobic. Topology studies suggest that most of the 
protein consists of six transmembrane helices separated 
by short hydrophilic loops (Feramisco et al., 2004). Only 
short sequences at the NH2 and COOH termini project into 
the cytoplasm. These sequences contain the major differ-
ences between the two Insigs. The NH2-terminal sequence 
of Insig-2 is 50 residues shorter than the sequence in 
Insig-1. The membranous regions of the two proteins (cor-
responding to amino acids 84–269 of Insig-1) are 85% 
identical. Both Insigs bind to cholesterol-loaded Scap, and 
both retain the Scap/SREBP complex in the ER (Yabe et 
al., 2002a; Adams et al., 2003).
Insigs appear to enhance the response to cholesterol 
by supporting cholesterol binding to Scap. Overexpress-
ing Insig-1 or Insig-2 lowers the threshold for producing 
the conformational changes in Scap that are detectable 
by trypsin digestion of membrane preparations (Adams et 
al., 2003). The most likely interpretation is that cholesterol 
dissociates readily from Scap, and dissociation is retarded 
when cholesterol-loaded Scap binds to Insigs, thereby 
locking cholesterol into the Insig/Scap/SREBP complex. 
Further insights into this process may emerge when the 
in vitro cholesterol binding assay can be performed using 
purified recombinant Scap with or without purified Insigs. 
This is technically challenging because it requires recon-
stituting the Scap/Insig interaction in detergent micelles 
rather than in membrane bilayers.
So far, the major differences between Insig-1 and Insig-
2 relate to the regulation of their expression (Yabe et al., 
2002a). Insig-1 is an obligatory SREBP target gene (Luong, 
2000; Janowski, 2002; Horton et al., 2002). Thus, the 
Insig-1 mRNA is produced only when cleaved SREBP is 
present in the nucleus, and transcription falls dramatically 
when SREBP processing is blocked. In contrast, Insig-2 is 
expressed at a low but constitutive level, at least in cultured 
cells. It is not regulated by SREBPs (Yabe et al., 2002a).
Inasmuch as Insig-1 transcription is dependent upon 
SREBPs, Insig-1 mRNA levels are regulated by cholesterol. 
Thus, Insig-1 mRNA rises when cells are sterol depleted, 
and it falls when cholesterol accumulates. Remarkably, the 
level of Insig-1 protein varies oppositely to the level of its 
mRNA, owing to sterol-regulated degradation. When cells 
are deprived of sterols, the Insig-1 protein is rapidly ubiq-
uitinated and degraded by proteasomes with a half-life of 
less than 30 min (Gong et al., 2006). When cholesterol is 
present, cholesterol-loaded Scap binds to Insig-1, thereby 
stabilizing Insig-1 and preventing its ubiquitination. Thus, in 
sterol-overloaded cells, Insig-1 has a relatively long half-life 
(>2 hr). This stabilization is totally dependent upon Scap. 
In Scap-deficient cells, cholesterol fails to stabilize Insig-1, 
and stability is restored by transfection of a cDNA encod-Cell 124, January 13, 2006 ©2006 Elsevier Inc. 37
ing wild-type Scap, but not any of the three mutant Scaps 
that cannot bind Insigs. In contrast to Insig-1, Insig-2 has 
a much longer half-life (Lee and Ye, 2004) that is not regu-
lated by sterols (Gong et al., 2006).
Convergent Feedback Inhibition
The regulation of Insig-1 at two levels (gene transcription 
and protein stability) sets the stage for a process that we 
have called “convergent feedback inhibition” (Figure 3). 
When cells have abundant cholesterol, Scap binds to Insig-
1, stabilizing the protein and leading to an accumulation of 
a stable Insig-1/Scap/SREBP complex. The nuclear con-
tent of SREBP falls and thus Insig-1 mRNA levels decline. 
The stable Insig-1/Scap/SREBP complex serves as a res-
ervoir for SREBP. When cells are acutely deprived of ste-
rols, Scap/SREBP dissociates from Insig-1, whereupon the 
latter is ubiquitinated and degraded in proteasomes (Gong 
et al., 2006). The liberated Scap/SREBP complex binds 
COPII proteins and moves to the Golgi complex where 
the SREBP is processed to its nuclear form. The nuclear 
SREBP turns on the genes for cholesterol biosynthesis and 
uptake through low-density lipoprotein (LDL) receptors. At 
the same time, the nuclear SREBP turns on the gene for 
Insig-1. This increases the amount of Insig-1 synthesis, but 
the protein will be rapidly degraded unless sufficient cho-
lesterol has accumulated to bind to Scap, allowing Scap 
Figure 3. Model for Convergent Feedback Inhibition of 
 Cholesterol Synthesis and Uptake
The essential feature of the model is that SREBP processing will not be 
blocked by sterols unless two SREBP-induced products converge on 
Scap simultaneously: (1) newly synthesized Insig-1, and (2) newly syn-
thesized or acquired cholesterol. This convergence assures that SREBP 
processing will not be terminated before the needs of the cell for choles-
terol and nonsterol isoprenoids are met (Gong et al., 2006).38 Cell 124, January 13, 2006 ©2006 Elsevier Inc.to stabilize Insig-1. Blocking of SREBP processing there-
fore requires the convergence of two molecules—newly 
supplied cholesterol (either from synthesis or uptake) and 
newly synthesized Insig-1 (Gong et al., 2006).
The reason for this convergence is not yet fully apparent. 
Figure 4. Mevalonate Pathway in Mammalian Cells
Acetyl-CoA is converted to cholesterol by at least 20 enzymes, all of 
whose genes are regulated by the SREBP pathway. Four key interme-
diates (mevalonate, farnesyl pyrophosphate, squalene, lanosterol) are 
highlighted in black boxes. Geranylgeranyl pyrophosphate, highlighted in 
the blue box, is a nonsterol isoprenoid derived from farnesyl pyrophos-
phate. Other nonsterol isoprenoids derived from farnesyl pyrophosphate 
(dolichol, heme A, ubiquinone) and from isopentyl pyrophosphate (iso-
pentyl group of tRNAs) are not shown.
It likely relates to the fact that SREBPs regulate the meval-
onate pathway, which produces vital isoprenoid end prod-
ucts in addition to cholesterol (Goldstein and Brown, 1990; 
Figure 4). If cholesterol alone could block SREBP process-
ing, and if cholesterol accumulated rapidly, the mevalonate 
pathway might be blocked before the other isoprenoids 
have accumulated to sufficient levels. The requirement for 
concurrent Insig-1 synthesis might be a failsafe mechanism 
that confirms that SREBP has entered the nucleus and 
turned on all of the genes of the mevalonate pathway.
Insigs Mediate Sterol-Triggered Degradation of 
HMG CoA Reductase
HMG CoA reductase is the first committed enzyme in the 
mevalonate pathway (Figure 4). As such, it is subjected 
to an extraordinary degree of regulation that maintains a 
steady flow of substrates for synthesis of nonsterol iso-
prenoids while preventing overproduction of cholesterol 
and potentially toxic cholesterol precursors (Goldstein and 
Brown, 1990). At the transcriptional level, the reductase is 
controlled by SREBPs, and gene transcription is thus sup-
pressed by cholesterol through the sterol-regulated trans-
port mechanism described above. At the posttranscrip-
tional level, the reductase is regulated by sterol-accelerated 
degradation. Remarkably, both processes are mediated by 
Insigs (Sever et al., 2003b).
HMG CoA reductase is bound to ER membranes 
through its NH2-terminal domain that contains eight TM 
helices (Roitelman et al., 1992; Figure 1). TM helices 2–6 
comprise the sterol-sensing domain (Hua et al., 1996a; 
Nohturfft et al., 1998a; Sever et al., 2003a). The COOH-ter-
minal domain of the reductase projects into the cytosol and 
contains the entire catalytic activity (Liscum et al., 1985). 
It is attached to the membrane domain by a proline-rich 
sequence that is predicted to be flexible and is readily pro-
teolyzed in vitro upon cell homogenization. The substrate 
and product of the enzyme are both water soluble, and the 
reason for membrane attachment is purely for regulation 
(Gil et al., 1985).
In sterol-deprived cells, HMG CoA reductase is degraded 
slowly with a half-life exceeding 12 hr. When sterols and 
other isoprenoids accumulate, the enzyme is degraded 
rapidly with a half-life of less than 1 hr. Degradation is 
mediated entirely by the membrane-attachment domain 
(Gil et al., 1985). Indeed, expression of the truncated 
soluble catalytic domain of the reductase fully restores 
cholesterol synthesis to reductase-deficient mutant CHO 
cells, but the soluble enzyme has a long half-life that is no 
longer accelerated by sterols (Gil et al., 1985). In contrast, 
the membrane domain undergoes sterol-accelerated deg-
radation, even when the catalytic domain is deleted (Sever 
et al., 2004).
The mechanism for sterol-regulated HMG CoA reductase 
degradation has been elucidated recently through studies 
of wild-type and mutant CHO cells. Remarkably, choles-
terol is only a weak inducer of this degradation. The cho-
lesterol precursor, lanosterol, is much more potent (Song et 
al., 2005a; Figure 4). A potential reason for this specificity Figure 5. Regulated Degradation of HMG CoA Reductase in 
Animal Cells
(A) The first step occurs when lanosterol triggers the binding of HMG 
CoA reductase to Insig-1 or Insig-2. Insig exists in a complex with a 
membrane-embedded E3 ubiquitin ligase, gp78. In turn, gp78 is bound 
to the E2 ubiquitin-conjugating enzyme Ubc7 and to VCP, an ATPase 
that plays a role in extracting ubiquitinated proteins from membranes. In 
the second step, the E3 activity of gp78 ubiquitinates the reductase. In 
the third step, the ubiquitinated HMG CoA reductase is extracted from 
the membrane by VCP and delivered to the proteasome for degradation. 
This postubiquitination step is stimulated by geranylgeraniol through an 
undefined mechanism that likely involves a geranylgeranylated protein, 
such as one of the Rab proteins.
(B) Domain structure of gp78. The location of transmembrane helices is 
predicted from hydropathy plots, but this topology has not been verified 
biochemically (Shimizu et al., 1999; Fang et al., 2001; Zhong et al., 2004).Cell 124, January 13, 2006 ©2006 Elsevier Inc. 39
is discussed in the next section. Accelerated degradation 
begins when lanosterol accumulates in ER membranes 
(Figure 5). This accumulation induces the reductase to 
bind to Insig-1, as demonstrated by coimmunoprecipitation 
(R.D.-B., unpublished data). By analogy to Scap regulation, 
it seems likely that lanosterol binds directly to the sterol-
sensing domain of HMG CoA reductase. However, so far 
it has been impossible to demonstrate this binding in vitro 
using the direct binding assay that was used to measure 
cholesterol binding to Scap. Moreover, we have not been 
able to detect a change in the tryptic cleavage pattern of 
the reductase upon lanosterol addition that is analogous to 
the change detected with Scap. Therefore, it remains pos-
sible that lanosterol does not bind to HMG CoA reductase 
directly, but rather to some other protein that induces the 
reductase to bind to Insigs.
HMG CoA reductase binding to Insigs requires the 
sequence YIYF in its sterol-sensing domain (Sever et al., 
2003a). Remarkably, the first tyrosine of this sequence is 
equivalent to tyrosine 298 of Scap, which is required for 
Scap binding to Insig (Nohturfft et al., 1998a; Adams et 
al., 2003). Indeed, transfection-mediated overexpression 
of Scap’s sterol-sensing domain competitively inhibits 
the Insig-mediated, sterol-accelerated degradation of the 
reductase, suggesting that the sterol-sensing domains 
from Scap and the reductase bind to the same sites on 
Insigs (Sever et al., 2003a). Like Scap, HMG CoA reductase 
binds to both Insig-1 and Insig-2 (Sever et al., 2003a).
How does Insig binding lead to degradation of HMG 
CoA reductase in animal cells? An early clue came from 
the observation that inhibitors of the proteasome block ste-
rol-stimulated degradation of the reductase, leading to the 
accumulation of ubiquitinated reductase within cells (Ravid 
et al., 2000). This ubiquitination was subsequently shown 
to be absolutely dependent on the action of either Insig-1 
or Insig-2 (Sever et al., 2003a). Ubiquitination of the reduc-
tase occurs on cytosolically exposed lysines 89 and 248, 
which lie immediately adjacent to transmembrane helices 
3 and 7 (Figure 1). There is no evidence for ubiquitination 
of the catalytic domain of the reductase. Indeed, as men-
tioned above, the catalytic domain is not required for ste-
rol-regulated degradation.
Coimmunoprecipitation experiments revealed that a 
fraction of Insig-1 molecules are bound constitutively to a 
protein named gp78 (Song et al., 2005b). As illustrated in 
Figure 5B, gp78 is a 643 amino acid protein with four iden-
tifiable domains (Shimizu et al., 1999; Fang et al., 2001): 
(1) an NH2-terminal membrane attachment region of 298 
amino acids that binds Insigs; (2) a 43-amino acid region 
that includes a RING finger consensus sequence confer-
ring E3 ubiquitin ligase activity; (3) a 42 amino acid region 
homologous to Cue1p, an ER membrane protein in yeast 
that serves as a membrane anchor for Ubc7p, a cytosolic 
ubiquitin-carrying E2 protein (Ponting, 2000); and (4) a 48 
amino acid region that mediates the interaction of gp78 
with VCP (Valosin-containing protein, also known as p97), 
an ATPase implicated in the postubiquitination steps of 
ER-associated protein degradation (ERAD; Zhong et al., 40 Cell 124, January 13, 2006 ©2006 Elsevier Inc.2004; Ye et al., 2005). ERAD is the process by which 
denatured ER proteins are retrotranslocated across the 
ER membrane for degradation by cytosolic proteasomes 
(Meusser et al., 2005).
Addition of lanosterol to intact cells triggers the bind-
ing of HMG CoA reductase to the Insig-1/gp78 complex 
(Figure 5A). Several lines of evidence indicate that this ste-
rol-triggered reductase/Insig-1/gp78 complex is essential 
for the ubiquitination and subsequent degradation of the 
reductase. First, reduction of gp78 levels by RNA interfer-
ence (RNAi) abrogated sterol-accelerated reductase ubiq-
uitination and degradation (Song et al., 2005b). Second, a 
truncated gp78 containing only its membrane domain and 
lacking its RING finger domain bound to Insig-1, displaced 
full-length gp78, and acted as a dominant-negative inhibi-
tor with respect to sterol-accelerated degradation of the 
reductase (Song et al., 2005b). These data indicate that 
the Insig-1/gp78 interaction occurs though the binding of 
the TM domains of the two proteins.
In addition to functioning as an E3 ubiquitin ligase, gp78 
also performs two other functions in HMG CoA reductase 
degradation. The Cue1p-like domain of mammalian gp78 
is known to bind Ubc7, an E2-conjugating enzyme (Fang 
et al., 2001). Preliminary evidence in the reductase system 
indicates that Ubc7 is indeed the E2 that supplies acti-
vated ubiquitin to the RING finger domain of gp78 (B.-L. 
Song and R.D.-B., unpublished data). The second func-
tion of gp78 is to link ubiquitination to degradation through 
its association with VCP, the ATPase that is implicated in 
ERAD. Indeed, VCP was recovered in the sterol-induced 
HMG CoA reductase/Insig-1/gp78 immunoprecipitate. 
Moreover, reduction of VCP levels with RNAi prevented 
the acceleration of reductase degradation in the presence 
of lanosterol (Song et al., 2005b).
Considered together, the current data on HMG CoA 
reductase degradation lead to the model shown in Figure 
5A. A fraction of membrane bound Insig-1 molecules are 
pre associated with gp78 and its attached Ubc7 and VCP 
molecules. Addition of lanosterol causes HMG CoA reduc-
tase to bind to this complex, whereupon the RING finger 
domain of gp78 transfers ubiquitin from Ubc7 to lysines 89 
and 248 of reductase (Sever et al., 2003a). Once sufficient 
ubiquitins have been transferred, VCP somehow extracts 
reductase from the ER membrane and delivers it to protea-
somes for degradation (Song et al., 2005b).
The complete extraction and degradation of ubiqui-
tinated HMG CoA reductase requires a nonsterol isopren-
oid derived from mevalonate (Goldstein and Brown, 1990; 
Sever et al., 2003a). Thus, if the mevalonate pathway is 
blocked by the reductase inhibitor compactin, lanos-
terol can still induce the binding of reductase to Insig-1 
and the subsequent ubiquitination. However, the ubiqui-
tinated reductase is not rapidly extracted from the ER and 
degraded unless the cells are also supplied with mevalon-
ate, the product of the reductase reaction. The mevalon-
ate requirement can be bypassed by supplying the cells 
with geranylgeraniol (GG-OH), a 20 carbon isoprenoid, 
but not with 15 carbon farnesol (Sever et al., 2003a). It 
Figure 6. Two Actions of Insigs in Cholesterol Homeostasis
Insigs regulate ER-to-Golgi transport of Scap/SREBP in a process that is inhibited by cholesterol. Insigs also regulate the ubiquitin-mediated proteasomal 
degradation of HMG CoA reductase in a process that is stimulated by lanosterol.is likely that GG-OH is converted to GG-pyrophosphate 
(GG-PP). The major product of GG-PP is the GG group 
that is attached covalently to selected cellular proteins. 
Such geranylgeranylated proteins include Rab proteins, 
which are known to participate in vesicular transport 
(Seabra et al., 2002).
An unsolved puzzle is the mechanism by which the eight 
membrane-spanning helices of HMG CoA reductase are 
extracted from the membrane and degraded in protea-
somes without ever releasing the catalytic domain into the 
cytosol. All of the ubiquitination occurs in the membranous 
domain of the reductase (Sever et al., 2003a), and the 
proteasomes presumably degrade this domain first. If an 
interior clip were made in the protease-susceptible linker 
between the membrane domain and the catalytic domain, 
the long-lived catalytic domain would be released into the 
cytosol, defeating the purpose of sterol-accelerated deg-
radation. The problem is compounded by the observation 
that the cytosolic domain of the reductase forms a tight tet-
ramer, as determined by X-ray crystallography (Istvan et al., 
2000). How does the proteasome unwind this tetramer? 
Are multiple proteasomes involved? Does the postulated 
requirement for a geranylgeranylated Rab protein indicate 
that a vesicular budding or fusion reaction is required? 
These questions may be answered when methods are 
developed to study the degradation of ubiquitinated reduc-
tase in vitro.
Insig Effects on Scap and HMG CoA Reductase: 
Parallels and Paradoxes
Figure 6 contrasts the effects of Insigs on Scap and HMG 
CoA reductase. In both cases, sterols trigger the binding 
of the respective sterol-sensing domains to Insigs, but that is where the similarity ends. The Scap/Insig interac-
tion blocks the binding of COPII proteins to Scap, allowing 
Scap/SREBP to remain in the ER in a stable complex with 
Insigs. Far from inducing degradation, the Scap/Insig com-
plex protects Insig-1 from ubiquitination and degradation. 
On the other hand, the reductase binds to a form of Insig-1 
that exists in a complex with gp78 and VCP. Binding leads 
to ubiquitination and degradation of the reductase through 
a mechanism that appears similar to the ERAD pathway for 
degradation of denatured ER proteins.
Why does Insig-1 binding not lead to the degradation of 
Scap as it does for HMG CoA reductase? One possibility 
for the lack of ubiquitination and degradation of Scap is 
that it binds to a fraction of Insig-1 that is not attached 
to gp78/VCP. Another possibility is that binding of Scap 
displaces gp78/VCP from Insig-1. Alternatively, binding 
of Scap to the Insig-1/gp78/VCP complex may somehow 
lead to the inhibition of the attached gp78. Finally, when 
the reductase binds to Insig-1, the membrane domain may 
be partially unfolded in a manner that allows it to be recog-
nized by gp78 as a denatured protein. On the other hand, 
Scap may remain in a tightly folded conformation that 
prevents it from being recognized as a gp78 substrate. 
Consistent with the latter hypothesis is the evidence that 
the reductase in yeast becomes unfolded when nonsterol 
metabolites bind to it, allowing the protein to be degraded 
through the standard ERAD mechanism (Shearer and 
Hampton, 2005). Each of these possibilities should be dis-
tinguishable with available tools of cell biology and protein 
biochemistry.
A significant difference in the regulation of Scap and 
HMG CoA reductase relates to sterol specificity (Figure 
6). Scap transport is regulated by the end-product cho-Cell 124, January 13, 2006 ©2006 Elsevier Inc. 41
lesterol, and the biosynthetic intermediate, lanosterol, 
has no effect on this process. In contrast, degradation of 
the reductase is regulated preferentially by lanosterol. An 
analysis of the mevalonate pathway provides a rational-
ization (Figure 4). The rationalization assumes that cells 
cannot tolerate the accumulation of lanosterol, which is 
known to be toxic (Xu et al., 2005). SREBPs stimulate 
transcription of all of the genes in the pathway, including 
the enzymes after lanosterol as well as the enzymes prior 
to lanosterol (Horton et al., 2003). If lanosterol were to 
accumulate and if this blocked SREBP processing, there 
would be a reduction in the enzymes necessary to convert 
lanosterol to cholesterol. This might actually increase the 
lanosterol accumulation. It seems more advantageous, 
therefore, to allow lanosterol to specifically stimulate the 
degradation of the reductase, which would prevent addi-
tional lanosterol synthesis while permitting high levels of 
the lanosterol-metabolizing enzymes. On the other hand, 
if the end-product cholesterol accumulates, the process-
ing of SREBPs is blocked, and this shuts down the whole 
pathway.
Oxysterol Regulation of Insig Binding to Scap and 
HMG CoA Reductase
In addition to cholesterol and lanosterol, the mevalon-
ate pathway is regulated potently by sterols that contain 
additional polar groups that increase hydrophilicity. Small 
amounts of oxysterols with hydroxyls at the 24, 25, or 27 
position are synthesized from cholesterol in various tis-
sues (Russell, 2000). The hydroxyl groups render the ste-
rols more water soluble than cholesterol, and hence they 
facilitate their excretion from cells. When added to cultured 
cells, 25-hydroxycholesterol causes both Scap (Adams et 
al., 2004) and HMG CoA reductase (Sever et al., 2003b) 
to bind to Insigs and thereby triggers all of the regulatory 
events. With regard to Scap, 25-hydroxycholesterol seems 
to act by an indirect mechanism. In contrast to cholesterol, 
25-hydroxycholesterol does not bind to recombinant Scap 
in the in vitro binding assay (Radhakrishnan et al., 2004), 
nor does it trigger the trypsin-detectable conformational 
change in Scap (Adams et al., 2004). Moreover, a pho-
toactivated derivative of cholesterol, but not 25-hydroxy-
cholesterol, crosslinks to Scap when added to cells or to 
isolated membranes (Adams et al., 2004). We postulate, 
therefore, that a separate 25-hydroxycholesterol binding 
protein mediates the effect of 25-hydroxycholesterol on 
Scap. It is possible that this same postulated protein also 
mediates oxysterol effects on the reductase.
Several years ago our laboratory purified and cloned a 
cytosolic oxysterol binding protein (OSBP-1; Dawson et al., 
1989) that translocates to Golgi membranes upon binding 
of 25-hydroxycholesterol (Ridgway et al., 1992). Attempts 
to demonstrate a role for this protein in Scap regulation 
have been unsuccessful. RNAi directed against OSBP-1 
reduced the protein level by more than 80%, but it did not 
affect 25-hydroxycholesterol inhibition of SREBP process-
ing. Overexpression of the predicted dominant-negative 
fragments of this protein also had no effect. More than 14 42 Cell 124, January 13, 2006 ©2006 Elsevier Inc.relatives of OSBP have been identified in the mammalian 
genome (Olkkonen, 2004), and it is possible that one of 
these relatives is a true regulator of Scap and/or HMG CoA 
reductase interaction with Insigs.
In the past, we have considered the possibility that oxy-
sterols do not act on Scap either directly or indirectly, but 
rather they act by increasing the cholesterol content of ER 
membranes (Brown et al., 2002). Indeed, in early stud-
ies, we showed that addition of 25-hydroxycholesterol to 
cultured cells leads to an increase in the esterification of 
cholesterol by an ER enzyme, implying that cholesterol 
has accumulated in the ER (Brown et al., 1975). A simi-
lar conclusion was reached by Lange and Steck (1997). 
Recent data renders this mechanism less likely to account 
for the oxysterol effect on Scap and HMG CoA reductase. 
If 25-hydroxycholesterol were acting by increasing ER cho-
lesterol, then we should have found an altered conforma-
tion of Scap as determined by the trypsin-cleavage assay. 
However, when 25-hydroxycholesterol was added to cells, 
no such change was observed, whereas a change was 
easily demonstrated when cholesterol was added (Brown 
et al., 2002; Adams et al., 2004). Moreover, when added to 
cells, the concentration of 25-hydroxycholesterol required 
to activate cholesterol esterification is orders of magnitude 
higher than that required to block SREBP processing or 
to accelerate reductase degradation. For this reason, we 
favor the idea of a specific (not-yet-identified) 25-hydroxy-
cholesterol binding protein.
Reciprocal Regulation of Insig-1 and -2 in Liver
In mammals, the liver is the organ most active in lipid syn-
thesis, and here SREBPs play special roles. In addition to 
cholesterol, the liver synthesizes large amounts of fatty 
acids, not only for its own membranes, but also for export 
to other tissues in lipoproteins. SREBPs control both pro-
cesses (Horton et al., 2002). The two prominent isoforms 
of SREBP in liver, SREBP-2 and SREBP-1c, have divergent 
but partially overlapping functions. SREBP-2 is primar-
ily involved in stimulating cholesterol synthesis, whereas 
SREBP-1c primarily stimulates fatty acid synthesis. In 
achieving the latter effect, SREBP-1c increases transcrip-
tion of all of the genes necessary to convert acetyl CoA to 
long-chain unsaturated fatty acids. In addition, SREBP-1c 
activates genes encoding the three enzymes that produce 
NADPH, which is required for synthesis of cholesterol as 
well as fatty acids, and the enzymes necessary to incorpo-
rate fatty acids into triglycerides and phospholipids (Horton 
et al., 2002).
Fatty acid synthesis in liver is controlled by two pancre-
atic hormones: insulin (which stimulates) and glucagon 
(which inhibits) (McGarry, 1998). The transcriptional effects 
of both hormones are mediated by changes in the amount 
of SREBP-1c. Insulin stimulates transcription of the SREBP-
1c gene (Kim et al., 1998; Horton et al., 1998; Shimomura 
et al., 1999; Foufelle and Ferre, 2002), and glucagon blocks 
this effect (Shimomura et al., 2000). Indirect evidence sug-
gests that insulin may also increase the processing of the 
SREBP-1c precursor to the mature form (Hegarty et al., 
2005). In liver, transcription of the SREBP-1c gene is also 
activated by nuclear receptors known as Liver X Recep-
tors (LXRs) (Repa et al., 2000; Chen et al., 2004). In cul-
tured cells, LXRs are potently activated by three oxysterols: 
24(S),25-epoxycholesterol, 22(R)-hydroxycholesterol, and 
27-hydroxycholesterol (Repa and Mangelsdorf, 2000). Two 
of these oxysterols (24(S),25-epoxycholesterol and 27-
hydroxycholesterol) also block SREBP processing. On the 
other hand, the most potent inhibitor of SREBP process-
ing, 25-hydroxycholesterol, is a relatively weak activator of 
LXRs. By increasing SREBP-1c levels in situations of sterol 
overload, the LXRs may assure a sufficient supply of fatty 
acids to allow storage of excess cholesterol as cholesteryl 
ester (Repa et al., 2000).
In keeping with its regulatory role in lipid synthesis, insu-
lin has profound effects on Insig isoforms in the liver. The 
liver produces an organ-specific isoform of Insig-2, desig-
nated Insig-2a (Yabe et al., 2003). The Insig-2a transcript 
differs from the ubiquitous transcript (Insig-2b) because it 
arises from an upstream promoter that produces a differ-
ent 5′ noncoding exon. This exon splices into the same 
coding exon that initiates Insig-2b. Thus, the Insig-2a and 
Insig-2b transcripts encode the same protein, but they dif-
fer in their pattern of regulation. Insig-2b is expressed at an 
extremely low level in liver. Insig-2a is transcribed at high 
levels only in liver, and only when insulin levels are low. The 
Insig-2a transcript is strongly repressed by insulin (Yabe et 
al., 2003).
The insulin-mediated regulation of Insigs in liver sets the 
stage for reciprocal regulation of Insig-1 and Insig-2 under 
conditions of fasting and feeding (Engelking et al., 2004). In 
fasted mice, insulin levels are low. As a result, the SREBP-
1c gene is not actively transcribed, nuclear SREBP-1c lev-
Figure 7. Reciprocal Changes in Expression of Insig-1 and 
Insig-2 in Livers of Mice Subjected to Fasting and Refeeding
The relative levels of Insig-1 and Insig-2a mRNA are shown from real-time 
PCR quantification (replotted from Figure 5 in Engelking et al. [2004]). The 
levels of Insig-1 and Insig-2a are similar in nonfasted mice. When mice are 
fasted, the expression of Insig-2a goes up dramatically, whereas expres-
sion of Insig-1 is decreased. Likewise, upon refeeding following a 12 hr 
fast, Insig-1 expression is greatly increased compared to the expression 
of Insig-2a. Similar trends were observed for Insig protein expression.els are low, and Insig-1 mRNA and protein levels are low. 
In contrast, Insig-2 levels are high, owing to the Insig-2a 
transcript. Upon feeding, insulin levels rise. This leads to a 
rapid reduction in Insig-2 mRNA and protein levels, owing 
to insulin-mediated repression of Insig-2a transcription. At 
the same time, insulin induces SREBP-1c transcription, 
nuclear SREBP-1c activates the Insig-1 gene, and Insig-1 
mRNA and protein levels rise to higher levels than in the 
basal nonfasting state. The net result is a replacement of 
Insig-2 by Insig-1. The striking reciprocal relation between 
Insig-1 and Insig-2 is illustrated in Figure 7.
In the fed state under the influence of insulin, SREBP-
1c is actively processed to its nuclear form in order to 
convert excess carbohydrate to fatty acids. Under these 
conditions, the purpose of fatty acid synthesis is energy 
storage rather than membrane maintenance, and it seems 
likely that the liver has specific mechanisms to override the 
SREBP feedback control mechanism. The Insig-2 to Insig-
1 switch may play a role in this override system.
To begin exploring these possibilities, knockout mice 
have been created in which the Insig-1 and Insig-2 genes 
are disrupted in liver through recombination (Engelking et 
al., 2005). Simultaneous germline disruption of both Insig 
genes was embryonically lethal. Therefore, the Insig-2 
gene was disrupted in the germline, and the Insig-1 gene 
was disrupted specifically in liver through an inducible Cre 
recombinase in adult animals. The resultant mice (des-
ignated L-Insig-1−/−;Insig-2−/−) appeared grossly normal. 
However, their livers were enlarged and full of cholesterol 
and triglycerides. Despite this lipid accumulation, the livers 
continued to synthesize fatty acids and cholesterol, owing 
to inappropriately high levels of mRNAs encoded by SREBP 
target genes and a dramatic increase (>100-fold) in HMG 
CoA reductase protein. The disproportionate increase in 
reductase protein is likely caused by slowed degradation in 
the absence of Insigs. Feeding of dietary cholesterol failed 
to reduce nuclear SREBPs and reductase protein and to 
suppress cholesterol synthesis in these livers, whereas 
prompt suppression was observed in matched wild-type 
animals. These findings confirmed that Insigs are required 
for feedback regulation of SREBP processing and reduc-
tase degradation in liver, as they are in cultured cells. More 
detailed studies will be required to define the specific roles 
of each Insig protein and to determine the metabolic con-
sequences of their reciprocal regulation.
Summary
It is noteworthy that the Scap/SREBP transport system 
and the HMG CoA reductase degradation system both 
make use of general mechanisms that cells use for many 
other proteins. Thus, Scap/SREBP is transported by clas-
sic COPII-coated vesicles, and the reductase appears to 
be degraded by the classic ERAD pathway. The unique 
feature of both the Scap/SREBP and reductase processes 
is regulation. In regulating cellular sterol concentrations, 
nature has engrafted a specific control mechanism upon 
two general processes. It is remarkable that the central 
regulator in both processes is the same protein—Insig.Cell 124, January 13, 2006 ©2006 Elsevier Inc. 43
ACknowLEDGMEnTS
The authors’ research is supported by the NIH (PO1-HL20948 and KO1-
HL70441) and the Perot Family Foundation. R.A.D.-B. is the recipient of 
an Established Investigator Award of the American Heart Association.
REFEREnCES
Adams, C.M., Goldstein, J.L., and Brown, M.S. (2003). Cholesterol-
induced conformational change in SCAP enhanced by Insig proteins 
and mimicked by cationic amphiphiles. Proc. Natl. Acad. Sci. USA 100, 
10647–10652.
Adams, C.M., Reitz, J., DeBrabander, J.K., Feramisco, J.D., Brown, 
M.S., and Goldstein, J.L. (2004). Cholesterol and 25-hydroxycholester-
ol inhibit activation of SREBPs by different mechanisms, both involving 
SCAP and insigs. J. Biol. Chem. 279, 52772–52780.
Antonny, B., and Schekman, R. (2001). ER export: public transporta-
tion by the COPII coach. Curr. Opin. Cell Biol. 13, 438–443.
Aridor, M., Weissman, J., Bannykh, S.I., Nuoffer, C., and Balch, W.E. 
(1998). Cargo selection by the COPII budding machinery during export 
from the ER. J. Cell Biol. 141, 61–70.
Barlowe, C. (2002). COPII-dependent transport from the endoplasmic 
reticulum. Curr. Opin. Cell Biol. 14, 417–422.
Brown, M.S., and Goldstein, J.L. (1997). The SREBP pathway: Regula-
tion of cholesterol metabolism by proteolysis of a membrane-bound 
transcription factor. Cell 89, 331–340.
Brown, M.S., and Goldstein, J.L. (1999). A proteolytic pathway that 
controls the cholesterol content of membranes, cells, and blood. Proc. 
Natl. Acad. Sci. USA 96, 11041–11048.
Brown, M.S., Dana, S.E., and Goldstein, J.L. (1975). Cholesteryl ester 
formation in cultured human fibroblasts: Stimulation by oxygenated ste-
rols. J. Biol. Chem. 250, 4025–4027.
Brown, A.J., Sun, L., Feramisco, J.D., Brown, M.S., and Goldstein, J.L. 
(2002). Cholesterol addition to ER membranes alters conformation of 
SCAP, the SREBP escort protein that regulates cholesterol metabolism. 
Mol. Cell 10, 237–245.
Chen, G., Liang, G., Ou, J., Goldstein, J.L., and Brown, M.S. (2004). 
Central role for liver X receptor in insulin-mediated activation of Srebp-
1c transcription and stimulation of fatty acid synthesis in liver. Proc. 
Natl. Acad. Sci. USA 101, 11245–11250.
Dawson, P.A., Ridgway, N.D., Slaughter, C.A., Brown, M.S., and Gold-
stein, J.L. (1989). cDNA cloning and expression of oxysterol binding 
protein, an oligomer with a potential leucine zipper. J. Biol. Chem. 264, 
16798–16803.
Engelking, L.J., Kuriyama, H., Hammer, R.E., Horton, J.D., Brown, 
M.S., Goldstein, J.L., and Liang, G. (2004). Overexpression of Insig-1 
in the livers of transgenic mice inhibits SREBP processing and reduces 
insulin-stimulated lipogenesis. J. Clin. Invest. 113, 1168–1175.
Engelking, L.J., Liang, G., Hammer, R.E., Takaishi, K., Kuriyama, H., 
Evers, B.M., Li, W.-P., Horton, J.D., Goldstein, J.L., and Brown, M.S. 
(2005). Schoenheimer Effect explained—feedback regulation of cho-
lesterol synthesis in mice mediated by Insig proteins. J. Clin. Invest. 
115, 2489–2498.
Espenshade, P.J., Cheng, D., Goldstein, J.L., and Brown, M.S. (1999). 
Autocatalytic processing of Site-1 protease removes propeptide and 
permits cleavage of sterol regulatory element-binding proteins. J. Biol. 
Chem. 274, 22795–22804.
Espenshade, P.J., Li, W.-P., and Yabe, D. (2002). Sterols block binding 
of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. 
Proc. Natl. Acad. Sci. USA 99, 11694–11699.
Fang, S., Ferrone, M., Yang, C., Jensen, J.P., Tiwari, S., and Weiss-
man, A.M. (2001). The tumor autocrine motility factor receptor, gp78, is 44 Cell 124, January 13, 2006 ©2006 Elsevier Inc.a ubiquitin protein ligase implicated in degradation from the endoplas-
mic reticulum. Proc. Natl. Acad. Sci. USA 98, 14422–14427.
Feramisco, J.D., Goldstein, J.L., and Brown, M.S. (2004). Membrane 
topology of human insig-1, a protein regulator of lipid synthesis. J. Biol. 
Chem. 279, 8487–8496.
Foufelle, F., and Ferre, P. (2002). New perspectives in the regulation of 
hepatic glycolytic and lipogenic genes by insulin and glucose: a role 
for the transcription factor sterol regulatory element binding protein-1c. 
Biochem. J. 366, 377–391.
Gil, G., Faust, J.R., Chin, D.J., Goldstein, J.L., and Brown, M.S. (1985). 
Membrane-bound domain of HMG CoA reductase is required for ste-
rol-enhanced degradation of the enzyme. Cell 41, 249–258.
Goldstein, J.L., and Brown, M.S. (1990). Regulation of the mevalonate 
pathway. Nature 343, 425–430.
Goldstein, J.L., Rawson, R.B., and Brown, M.S. (2002). Mutant mam-
malian cells as tools to delineate the sterol regulatory element-binding 
protein pathway for feedback regulation of lipid synthesis. Arch. Bio-
chem. Biophys. 397, 139–148.
Gong, Y., Lee, J.N., Lee, P.C.W., Goldstein, J.L., Brown, M.S., and 
Ye, J. (2006). Sterol-regulated ubiquitination and degradation of Insig-1 
creates a convergent mechanism for feedback control of cholesterol 
synthesis and uptake. Cell Metab. 3, 15–24.
Hegarty, B.D., Bobard, A., Hainault, I., Ferre, P., Bossard, P., and 
Foufelle, F. (2005). Distinct roles of insulin and liver X receptor in the 
induction and cleavage of sterol regulatory element-binding protein-1c. 
Proc. Natl. Acad. Sci. USA 102, 791–796.
Horton, J.D., Bashmakov, Y., Shimomura, I., and Shimano, H. (1998). 
Regulation of sterol regulatory element binding proteins in livers of fast-
ed and refed mice. Proc. Natl. Acad. Sci. USA 95, 5987–5992.
Horton, J.D., Goldstein, J.L., and Brown, M.S. (2002). SREBPs: activa-
tors of the complete program of cholesterol and fatty acid synthesis in 
the liver. J. Clin. Invest. 109, 1125–1131.
Horton, J.D., Shah, N.A., Warrington, J.A., Anderson, N.N., Park, 
S.W., Brown, M.S., and Goldstein, J.L. (2003). Combined analysis 
of olignucleotide microarray data from transgenic and knockout mice 
identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 100, 
12027–12032.
Hua, X., Nohturfft, A., Goldstein, J.L., and Brown, M.S. (1996a). Sterol 
resistance in CHO cells traced to point mutation in SREBP cleavage 
activating protein (SCAP). Cell 87, 415–426.
Hua, X., Sakai, J., Brown, M.S., and Goldstein, J.L. (1996b). Regu-
lated cleavage of sterol regulatory element binding proteins (SREBPs) 
requires sequences on both sides of the endoplasmic reticulum mem-
brane. J. Biol. Chem. 271, 10379–10384.
Istvan, E.S., Palnitkar, M., Buchanan, S.K., and Deisenhofer, J. (2000). 
Crystal structure of the catalytic portion of human HMG-CoA reduc-
tase: Insights into regulation of activity and catalysis. EMBO J. 19, 
819–830.
Janowski, B.A. (2002). The hypocholesterolemic agent LY295427 up-
regulates INSIG-1, identifying the INSIG-1 protein as a mediator of 
cholesterol homeostasis through SREBP. Proc. Natl. Acad. Sci. USA 
99, 12675–12680.
Kim, J.B., Sarraf, P., Wright, M., Yao, K.M., Mueller, E., Solanes, G., 
Lowell, B.B., and Spiegelman, B.M. (1998). Nutritional and insulin 
regulation of fatty acid synthetase and leptin gene expression through 
ADD1/SREBP1. J. Clin. Invest. 101, 1–9.
Lange, Y., and Steck, T.L. (1997). Quantitatnion of the pool of choles-
terol associated with acyl-CoA: Cholesterol acyltransferase in human 
fibroblasts. J. Biol. Chem. 272, 13103–13108
Lee, J.N., and Ye, J. (2004). Proteolytic activation of sterol regulatory 
element-binding protein induced by cellular stress through depletion of 
Insig-1. J. Biol. Chem. 279, 45257–45265.
Lee, P.C.W., Sever, N., and DeBose-Boyd, R.A. (2005). Isolation of ste-
rol-resistant Chinese hamster ovary cells with genetic deficiencies in 
both Insig-1 and Insig-2. J. Biol. Chem. 280, 25242–25249.
Liscum, L., Finer-Moore, J., Stroud, R.M., Luskey, K.L., Brown, M.S., 
and Goldstein, J.L. (1985). Domain structure of 3-hydroxy-3-methylglu-
taryl coenzyme A reductase, a glycoprotein of the endoplasmic reticu-
lum. J. Biol. Chem. 260, 522–530.
Luong, A. (2000). Identification of three novel SREBP-activated target 
genes: acetyl CoA synthetase, 3-β-hydroxysterol dehydrogenase, and 
CL-6/INSIG1. Ph.D. dissertation. (Dallas: University of Texas South-
western Medical Center at Dallas), pp. 1–137.
McGarry, J.D. (1998). Glucose-fatty acid interactions in health and dis-
ease. Am. J. Clin. Nutr. 67 (Suppl.), 500S–504S.
Meusser, B., Hirsch, C., Jarosch, E., and Sommer, T. (2005). ERAD: the 
long road to destruction. Nat. Cell Biol. 7, 766–772.
Mohn, K.L., Laz, T.M., Hsu, J.-C., Melby, A.E., Bravo, R., and Taub, R. 
(1991). The immediate-early growth response in regenerating liver and 
insulin-stimulated H-35 cells: comparison with serum-stimulated 3T3 
cells and identification of 41 novel immediate-early genes. Mol. Cell. 
Biol. 11, 381–390.
Nohturfft, A., Brown, M.S., and Goldstein, J.L. (1998a). Sterols regu-
late processing of carbohydrate chains of wild-type SREBP cleavage-
activating protein (SCAP), but not sterol-resistant mutants Y298C or 
D443N. Proc. Natl. Acad. Sci. USA 95, 12848–12853.
Nohturfft, A., Brown, M.S., and Goldstein, J.L. (1998b). Topology of 
SREBP cleavage-activating protein, a polytopic membrane protein with 
a sterol-sensing domain. J. Biol. Chem. 273, 17243–17250.
Nohturfft, A., Yabe, D., Goldstein, J.L., Brown, M.S., and Espenshade, 
P.J. (2000). Regulated step in cholesterol feedback localized to bud-
ding of SCAP from ER membranes. Cell 102, 315–323.
Olkkonen, V.M. (2004). Oxysterol binding protein and its homologues: 
new regulatory factors involved in lipid metabolism. Curr. Opin. Lipidol. 
15, 321–327.
Peng, Y., Schwarz, E.J., Lazar, M.A., Genin, A., Spinner, N.B., and 
Taub, R. (1997). Cloning, human chromosomal assignment, and adi-
pose and hepatic expression of the CL-6/INSIG1 gene. Genomics 43, 
278–284.
Ponting, C.P. (2000). Proteins of the endoplasmic-reticulum-associated 
degradation pathway: domain detection and function prediction. Bio-
chem. J. 351, 527–535.
Radhakrishnan, A., Sun, L.-P., Kwon, H.J., Brown, M.S., and Gold-
stein, J.L. (2004). Direct binding of cholesterol to the purified mem-
brane region of SCAP: mechanism for a sterol-sensing domain. Mol. 
Cell 15, 259–268.
Ravid, T., Doolman, R., Avner, R., Harats, D., and Roitelman, J. (2000). 
The ubiquitin-proteasome pathway mediates the regulated degradation 
of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. 
Biol. Chem. 275, 35840–35847.
Repa, J.J., and Mangelsdorf, D.J. (2000). The role of orphan nuclear 
receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell 
Dev. Biol. 16, 459–481.
Repa, J.J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M.A., Shi-
momura, I., Shan, B., Brown, M.S., Goldstein, J.L., and Mangelsdorf, 
D.J. (2000). Regulation of mouse sterol regulatory element-binding 
protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. 
Genes Dev. 14, 2819–2830.
Ridgway, N.D., Dawson, P.A., Ho, Y.K., Brown, M.S., and Goldstein, 
J.L. (1992). Translocation of oxysterol binding protein to Golgi appara-
tus triggered by ligand binding. J. Cell Biol. 116, 307–319.
Roitelman, J., Olender, E.H., Bar-Nun, S., Dunn, W.A., Jr., and Simoni, R.D. (1992). Immunological evidence for eight spans in the membrane 
domain of 3-hydroxy-3-methylglutaryl Coenzyme A reductase: implica-
tions for enzyme degradation in the endoplasmic reticulum. J. Cell Biol. 
117, 959–973.
Russell, D.W. (2000). Oxysterol biosynthetic enzymes. Biochim. Bio-
phys. Acta 1529, 126–135.
Sakai, J., Nohturfft, A., Cheng, D., Ho, Y.K., Brown, M.S., and Gold-
stein, J.L. (1997). Identification of complexes between the COOH-ter-
minal domains of sterol regulatory element binding proteins (SREBPs) 
and SREBP cleavage-activating protein (SCAP). J. Biol. Chem. 272, 
20213–20221.
Seabra, M.C., Mules, E.H., and Hume, A.N. (2002). Rab GTPases, in-
tracellular traffic and disease. Trends Mol. Med. 8, 23–30.
Sever, N., Song, B.-L., Yabe, D., Goldstein, J.L., Brown, M.S., and 
DeBose-Boyd, R.A. (2003a). Insig-dependent ubiquitination and deg-
radation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase 
stimulated by sterols and geranylgeraniol. J. Biol. Chem. 278, 52479–
52490.
Sever, N., Yang, T., Brown, M.S., Goldstein, J.L., and DeBose-Boyd, 
R.A. (2003b). Accelerated degradation of HMG CoA reductase medi-
ated by binding of Insig-1 to its sterol-sensing domain. Mol. Cell 11, 
25–33.
Sever, N., Lee, P.C.W., Song, B.-L., Rawson, R.B., and DeBose-Boyd, 
R.A. (2004). Isolation of mutant cells lacking Insig-1 through selection 
with SR-12813, an agent that stimulates degradation of 3-hydroxy-
3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 279, 43136–
43147.
Shearer, A.G., and Hampton, R.Y. (2005). Lipid-mediated, reversible 
misfolding of a sterol-sensing domain protein. EMBO J. 24, 149–159.
Shimizu, K., Tani, M., Watanabe, H., Nagamachi, Y., Niinaka, Y., Shiroi-
shi, T., Ohwada, S., Raz, A., and Yokota, J. (1999). The autocrine motil-
ity factor receptor gene encodes a novel type of seven transmembrane 
protein. FEBS Lett. 456, 295–300.
Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J.D., Brown, M.S., 
and Goldstein, J.L. (1999). Insulin selectively increases SREBP-1c 
mRNA in livers of rats with streptozotocin-induced diabetes. Proc. Natl. 
Acad. Sci. USA 96, 13656–13661.
Shimomura, I., Matsuda, M., Hammer, R.E., Bashmakov, Y., Brown, 
M.S., and Goldstein, J.L. (2000). Decreased IRS-2 and increased 
SREBP-1c lead to mixed insulin resistance and sensitivity in livers of 
lipodystrophic and ob/ob mice. Mol. Cell 6, 77–86.
Skalnik, D.G., Narita, H., Kent, C., and Simoni, R.D. (1988). The mem-
brane domain of 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
confers endoplasmic reticulum localization and sterol-regulated degra-
dation onto β-galactosidase. J. Biol. Chem. 263, 6836–6841.
Song, B.-L., Javitt, N.B., and DeBose-Boyd, R.A. (2005a). Insig-medi-
ated degradation of HMG CoA reductase stimulated by lanosterol, an 
intermediate in the synthesis of cholesterol. Cell Metab. 1, 179–189.
Song, B.-L., Sever, N., and DeBose-Boyd, R.A. (2005b). Gp78, a mem-
brane-anchored ubiquitin ligase, associates with Insig-1 and couples 
sterol-regulated ubiquitination to degradation of HMG CoA reductase. 
Mol. Cell 19, 829–840.
Sun, L.-P., Li, L., Goldstein, J.L., and Brown, M.S. (2005). Insig re-
quired for sterol-mediated inhibition of Scap/SREBP binding to COPII 
proteins in vitro. J. Biol. Chem. 280, 26483–26490.
Xu, F., Rychnovsky, S.D., Belani, J.D., Hobbs, H.H., Cohen, J.C., and 
Rawson, R.B. (2005). Dual roles for cholesterol in mammalian cells. 
Proc. Natl. Acad. Sci. USA 102, 14551–14556.
Yabe, D., Brown, M.S., and Goldstein, J.L. (2002a). Insig-2, a second 
endoplasmic reticulum protein that binds SCAP and blocks export of 
sterol regulatory element-binding proteins. Proc. Natl. Acad. Sci. USA 
99, 12753–12758.Cell 124, January 13, 2006 ©2006 Elsevier Inc. 45
Yabe, D., Xia, Z.-P., Adams, C.M., and Rawson, R.B. (2002b). Three 
mutations in sterol-sensing domain of SCAP block interaction with insig 
and render SREBP cleavage insensitive to sterols. Proc. Natl. Acad. 
Sci. USA 99, 16672–16677.
Yabe, D., Komuro, R., Liang, G., Goldstein, J.L., and Brown, M.S. 
(2003). Liver-specific mRNA for Insig-2 down-regulated by insulin: 
Implications for fatty acid synthesis. Proc. Natl. Acad. Sci. USA 100, 
3155–3160.
Yang, T., Goldstein, J.L., and Brown, M.S. (2000). Overexpression of 
membrane domain of SCAP prevents sterols from inhibiting SCAP/
SREBP exit from endoplasmic reticulum. J. Biol. Chem. 275, 29881–
29886.
Yang, T., Espenshade, P.J., Wright, M.E., Yabe, D., Gong, Y., Aebersold, 
R., Goldstein, J.L., and Brown, M.S. (2002). Crucial step in cholesterol 46 Cell 124, January 13, 2006 ©2006 Elsevier Inc.homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane 
protein that facilitates retention of SREBPs in ER. Cell 110, 489–500.
Ye, Y., Shibata, Y., Kikkert, M., van Voorden, S., Wiertz, E., and Rapo-
port, T.A. (2005). Recruitment of the p97 ATPase and ubiquitin ligases 
to the site of retrotranslocation at the endoplasmic reticulum mem-
brane. Proc. Natl. Acad. Sci. USA 102, 14132–14138.
Zelenski, N.G., Rawson, R.B., Brown, M.S., and Goldstein, J.L. (1999). 
Membrane topology of S2P, a protein required for intramembranous 
cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 
274, 21973–21980.
Zhong, X., Shen, Y., Ballar, P., Apostolou, A., Agami, R., and Fang, 
S. (2004). AAA ATPase p97/valosin-containing protein interacts with 
gp78, a ubiquitin ligase for endoplasmic reticulum-associated degrada-
tion. J. Biol. Chem. 279, 45676–45684.
